NOVARTIS - PASPORT Head to Head Study positive: Sandostatin LAR Replacement Ready in active acromegaly
Novartis today presented the pasireotide LAR PhIII study data in treatment naïve patients (post surgery) acromegaly patients at the 15th International Congress of Endocrinology. The data revealed that more number of patients treated with pasireotide LAR had full control of their disease than Sandostatin LAR – 63% better than Sandostatin LAR (31.3% vs. 19.2%). The safety profile of pasireotide was similar to Sandostatin except hyperglycemia (29% vs 8.3%). In another 6-month extension study, in which patients who did not achieve full biochemical control were allowed to switch to other treatments, after 6 months of switching to new treatment, 21% of those who switched to SOM230 attained full control as compared to 2.6% of those who switched to Sandostatin LAR SOM 230 is also being explored in another Phase 3 study head to head with open label Sandostatin and Lanreotide ATG in patients with inadequately controlled Acromegaly. The study will report data in 2H 2013. The significant clinical benefit of pasireotide LAR over Sandostatin LAR will allow the company to retain its sales despite expected competition (Table 1) and beyond the patent expiry of Sandostatin LAR in 2014 (2011 sales $1.4b).
COMPANIES MENTIONED
NOVARTIS
NOVARTIS
